Humanized anti-CD117 Monoclonal Antibody (JSP191)

BIOLOGICAL2 trials

Sponsors

Jasper Therapeutics, Inc.

Conditions

ACUTE MYELOID LEUKEMIA; AMLMYELODYSPLASTIC SYNDROME; MDSSCID

Phase 1

JSP191 Antibody Targeting Conditioning in SCID Patients

TerminatedNCT02963064

Jasper Therapeutics, Inc.SCID

Start: 2017-03-20End: 2025-07-07Updated: 2025-07-28

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Jasper Therapeutics, Inc.ACUTE MYELOID LEUKEMIA; AML, MYELODYSPLASTIC SYNDROME; MDS

Start: 2020-07-08End: 2023-12-08Target: 40Updated: 2021-06-11

Related Papers

Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS

Blood2026-03-05

Safe Regimen for Patients Undergoing Stem Cell Transplantation

Oncology Times2023-04-19

JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID)

Blood2021-11-0511 citations

Early results of phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with non-myeloablative conditioning in older adults with MRD-positive MDS/AML undergoing allogeneic hematopoietic cell transplantation.

Journal of Clinical Oncology2021-05-209 citations

Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency

Blood2019-11-1327 citations